Anthropic, Roche & NVIDIA: This Week's Top Stories

UK Gov: Decreasing Healthcare Pressure With Fast Food Ad Ban

The UK government has introduced new measures targeting the pervasive issue of childhood obesity.

By focusing on restricting junk food advertising, these initiatives aim to remove up to 7.2 billion calories from children's diets each year.

This step is seen as a pivotal part of the broader strategy to nurture healthier eating habits among young people.

A Guide to Anthropic's New AI Model for Healthcare Support

After OpenAI launched the ChatGPT Health feature, Anthropic has introduced Claude for Healthcare, which provides personalised health advice.

This expands on its previous model, Claude for Life Sciences, which focuses on the scientific research side of the healthcare sector.

Anthropic’s new model aims to support consumers with medical guidance, as well as healthcare providers.

Roche: Making Preventative Healthcare Accessible to All

Roche is one of the world’s largest biotechnology companies, growing to become a leading provider of transformative solutions since its founding more than 125 years ago.

It focuses on preventing, stopping or altogether curing diseases with the highest societal burden in order to improve health outcomes and reduce costs.

Roche says: “From developing diagnostics and treatments, to harnessing the power of data to shape innovations of the future, we are a healthcare company with a culture of integrity, courage and passion.”

How J&J is Boosting Medicine Manufacturing in the US

Global healthcare leader Johnson & Johnson (J&J) has entered into a voluntary agreement with the Trump Administration aimed at expanding patient access to medicines while cutting costs for millions of Americans.

The deal aligns the "innovation powerhouse" with President Donald Trump’s call for the pharmaceutical industry to adopt a most-favoured-nation pricing model.

It coincides with J&J’s commitment to build two new facilities – a next-generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug production facility in North Carolina.

NVIDIA and Eli Lilly Target AI Medicine Manufacturing

The pharmaceutical industry could be on the cusp of a manufacturing revolution as NVIDIA and Eli Lilly (Lilly) announce a US$1bn investment in an AI-powered co-innovation lab.

The partnership aims to address some of healthcare's most pressing challenges, from accelerating medicine discovery to strengthening pharmaceutical supply chains that serve patients worldwide.

The collaboration brings together Lilly's nearly 150 years of pharmaceutical expertise with NVIDIA's AI and computing capabilities.

By combining these strengths, the companies hope to tackle critical healthcare challenges, including lengthy drug development timelines and manufacturing capacity constraints that can limit patient access to essential medicines.